Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 114, Issue -, Pages 206-221Publisher
ELSEVIER
DOI: 10.1016/j.addr.2017.04.010
Keywords
Tumor-associated macrophage; Cancer immunotherapy; Drug delivery; Targeted therapy; Tumor microenvironment
Categories
Funding
- NIH [1R01CA177272]
- Anandamahidol Foundation Fellowship
- Cardiovascular Pathology Training Grant [NIH 5T32HL0071312]
Ask authors/readers for more resources
As an essential innate immune population for maintaining body homeostasis and warding off foreign pathogens, macrophages display high plasticity and perform diverse supportive functions specialized to different tissue compartments. Consequently, aberrance in macrophage functions contributes substantially to progression of several diseases including cancer, fibrosis, and diabetes. In the context of cancer, tumor-associated macrophages (TAMs) in tumor microenvironment (TME) typically promote cancer cell proliferation, immunosuppression, and angiogenesis in support of tumor growth and metastasis. Oftentimes, the abundance of TAMs in tumor is correlated with poor disease prognosis. Hence, significant attention has been drawn towards development of cancer immunotherapies targeting these TAMs; either depleting them from tumor, blocking their pro-tumoral functions, or restoring their immunostimulatory/tumoricidal properties. This review aims to introduce readers to various aspects in development and evaluation of TAM-targeted therapeutics in pre-clinical and clinical stages. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available